Abstract: Non-immunosuppressive, cyclophilin-binding cyclosporins, in particular, [Melle]4-Ciclosporin, are useful as neuroprotective agents, e.g., in the prevention or treatment of cerebral ischemia or traumatic brain or spinal cord injury.

Abstract: The present invention relates to novel uses of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders.

Abstract: We have found that Deprenyl® induces a novel polypeptide in neural cells. This polypeptide has the structure given in SEQ ID No. 1 and is referred to herein as DIP 1 (Deprenyl® Induced Protein 1).

Abstract: Pyridine derivatives of the formula ##STR1## their tautomers and their salts, in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and n have the meanings given in the claims, can be used as active ingredients in medicaments and are manufactured in a manner known per se.

Abstract: The invention relates to pharmaceutical compositions which contain, as active ingredients, a butyrophenone derivative I which is basically substituted in the 4-position and has central depressant and antipsychotic activity, or a pharmaceutically acceptable acid addition salt thereof, and an unsubstituted or substituted C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydropyridine of the general formula II ##STR1## wherein R.sub.1 is hydrogen, an alkyl group containing at most 4 carbon atoms, the allyl, 3-oxobutyl, 3-hydroxybutyl, 2-propynyl or cyclopropylmethyl group, R.sub.2 is hydrogen or a methyl group, R.sub.3 is hydrogen, halogen having an atomic number up to 35, a lower alkyl or alkoxy group, the trifluoromethyl group or a cycloalkyl group containing 5 to 8 carbon atoms, R.sub.4 is hydrogen, a lower alkyl group or halogen having an atomic number up to 35, or R.sub.3 and R.sub.